NATALEE: Phase III study of ribociclib (RIBO) plus endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).

被引：43

作者：

Slamon, Dennis J.

Fasching, Peter A.

Patel, Ravindranath

Verma, Sunil

Hurvitz, Sara A.

Chia, Stephen K. L.

Crown, John

Martin, Miguel

Barrios, Carlos H.

Spera, Gonzalo

Lopez, Celine

Hor, Ines

Pelov, Diana

Hughes, Gareth

Nawinne, Moditha

Hortobagyi, Gabriel N.

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[2] Univ Hosp Erlangen, Erlangen, Germany

[3] Comprehens Blood & Canc Ctr, Bakersfield, CA USA

[4] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[5] BC Canc Agcy, Vancouver, BC, Canada

[6] St Vincents Univ Hosp, Dept Med Oncol, Dublin, Ireland

[7] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain

[8] Latin Amer Cooperat Oncol Grp, Porto Alegre, RS, Brazil

[9] Translat Res Oncol, Montevideo, Uruguay

[10] Translat Res Oncol TRIO, Paris, France

[11] Novartis Pharmaceut, E Hanover, NJ USA

[12] Novartis Pharma AG, Basel, Switzerland

[13] Novartis Pharma AG, Basil, Switzerland

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.TPS597

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS597

引用

页数：2